Decreased proliferative responses to mitogens and recall Ags have been observed in PBMC obtained during several acute human viral infections. To determine whether cell-mediated responses are altered during acute dengue infection, we examined the proliferative responses of PBMC from children enrolled in a prospective study of dengue infections in Thailand. All responses of PBMC during acute illness were compared with the same patients’ PBMC obtained at least 6 mo after their infection. Proliferative responses to PHA, anti-CD3, tetanus toxoid, and dengue Ags were decreased significantly in PBMC obtained during the acute infection. The proliferative responses to PHA were restored by the addition of gamma-irradiated autologous convalescent or allogeneic PBMC. Cell contact with the irradiated PBMC was necessary to restore proliferation. Non-T cells from the acute PBMC of dengue patients did not support proliferation of T cells from control donors in response to PHA, but T cells from the PBMC of patients with acute dengue proliferated if accessory cells from a control donor were present. Addition of anti-CD28 Abs restored anti-CD3-induced proliferation of the PBMC of some patients. The percentage of monocytes was reduced in the acute sample of PBMC of the dengue patients. Addition of IL-2 or IL-7, but not IL-4 or IL-12, also restored proliferation of acute PBMC stimulated with anti-CD3. The results demonstrate that both quantitative and qualitative defects in the accessory cell population during acute dengue illness result in a depression of in vitro T cell proliferation.

Several acute viral infections such as measles, CMV, and HIV have been associated with transient immunosuppression of cell-mediated responses both in vivo and in vitro (1, 2). This immunosuppression has been characterized by decreased T cell proliferative responses to mitogens such as PHA or to specific recall Ags such as purified protein derivative and tetanus toxoid. A number of different mechanisms have been proposed to explain the immunosuppression seen during and following an acute viral infection (3). To date no single cell type or factor has been shown to be solely responsible for the defects seen during an acute viral infection. It is likely, however, that one mechanism may not fully explain the immunologic abnormalities observed and that a series of events in succession may result in the observed depression of cellular immune responses both in vivo and in vitro (4).

The in vitro proliferation of PBMC from patients with measles infection can be improved by the addition of rIL-2, which suggests inadequate production of this cytokine by T cells (5). PBMC from measles patients produce more IL-1 and less TNF than control patients in vitro, which may also contribute to the decreased proliferation seen (6, 7). The lymphopenia seen during measles includes reductions of both T and B cells, but the ratio of CD4/CD8 T cells is not altered (7, 8). Production of IFN-γ is low to normal, and IL-4 levels are elevated in vitro, implying that Th2 cells are activated (7, 9). These immunologic deficiencies occur in the context of significant in vivo immune activation, as evidenced by increases in plasma levels of soluble CD4 (sCD4),4 sCD8, sIL-2R, and β2 microglobulin.

The role of costimulatory molecules in mediating the immunologic unresponsiveness seen in acute viral infections has not been reported. CD28-B7 interactions have been shown to be essential for initiating immune responses, up-regulating cytokine production, and promoting T cell differentiation in various systems (10). Triggering of the TCR in the absence of costimulatory signals has been shown to inhibit T cell responses in several in vitro systems (11). On the other hand, elevations of the costimulatory molecules B7-1 and B7-2 on APCs have been associated with autoimmune disorders such as rheumatoid arthritis and systemic lupus erythematosis (12, 13).

Patients with dengue hemorrhagic fever (DHF) have been shown to have elevated circulating levels of IFN-γ, IL-2, sCD4, sCD8, and sIL-2R, which are markers of T cell activation, similar to what has been reported in severe measles infection (14). Children are leukopenic for several days during acute dengue virus infection with a decrease in the absolute number of neutrophils and monocytes (15). The absolute T cell count and the CD4/CD8 ratios are not altered during acute dengue illness. The leukopenia is thought to be related to bone marrow suppression induced by dengue virus (16). This decrease is temporary, and monocyte counts return to normal within a few days. We studied the proliferative responses of PBMC to Ags and mitogens from children with acute dengue to determine whether T cell responses were reduced.

Our results indicate that in vitro proliferation of T cells to a wide variety of stimuli is suppressed during acute dengue infection. The accessory cells obtained from PBMC during acute infection do not provide an adequate stimulus to enable proliferation of the T cells, whereas the T cells from acute PBMC can proliferate if provided with competent accessory cells. The decreased responses of T cells in the samples of acute PBMC were also partially restored upon the addition of exogenous IL-2 and IL-7. Anti-CD28 Abs improved proliferative responses of CD3-stimulated acute PBMC in some subjects. The decrease in costimulatory and adhesion molecules due to the decreased number of monocytes may contribute to the immunosuppressive effects seen in vitro using PBMC obtained during acute dengue infection. These observations suggest that during acute dengue infection, the principal defect in the ability of T cells to proliferate is due to the accessory cell population.

PBMC were obtained from children enrolled in a prospective study of dengue infections at the Queen Sirikit National Institute of Child Health (the Bangkok Children’s Hospital, Bangkok, Thailand) and the Kamphaeng Phet Provincial Hospital (Kamphaeng Phet, Thailand) (15, 17). Children were eligible to participate in the study if they were febrile and had no obvious source of infection for <72 h. A child was diagnosed as having acute dengue infection when the serologic tests were positive and/or dengue virus was isolated from the blood. Clinical diagnoses of dengue fever (DF) and DHF were assigned according to WHO criteria (18). Study day 1 was defined as the calendar day on which the subject was enrolled in the study. For these studies, a sample was considered to be an acute sample up to study day 11, although the subjects were not febrile at that time. Convalescent samples were obtained from the same patients 6 mo or later after their acute infection. All sample numbers in this manuscript are denoted by the study days on which the samples were obtained. Fever day 0 was defined as the calender day during which the temperature fell and stayed <38°C, and days before and after this point were numbered consecutively (fever days −1, −2, etc., occurred before defervescence, and fever days +1, +2, etc., occurred after defervescence). Patient information and the diagnoses are given in Table I. Sample numbers indicate acute (A) or convalescent (C) PBMC and the study day on which they were obtained. The average age of the patients included in the study was 8 yr (SD 2.48). PBMC were separated, cryopreserved, and stored in liquid nitrogen until use. The PBMC were shipped to the University of Massachusetts Medical Center on dry ice for testing.

Table I.

Summary of patient information and clinical diagnosis

PatientDiagnosisSerologic ResponseSerotypeAcute/Conv. BleedaStudy DayFever Dayb
1 (CHD94-090) DF Primary D1 4, 11 −1, +6 
    374  
2 (CHD94-067) DF Primary D2 1, 11 −2, +8 
    368  
3 (CHD94-139) DF Secondary D1 2, 3 0, +1 
    354  
4 (KPP94-017) DF Secondary D2 −1 
    366  
5 (CHD94-115) DF Secondary D3 +8 
    725  
6 (CHD94-089) DF Secondary D3 2, 10 −1, +7 
    725  
7 (CHD94-118) DF Secondary D4 2, 3 0, +1 
    367  
8 (KPP94-013) DF Secondary D4 −1 
    364  
9 (CHD94-094) DHF grade 1 Secondary D4 −1 
    336, 725  
10 (CHD94-073) DHF grade 2 Secondary D4 +5 
    368  
11 (CHD94-020) DHF grade 2 Secondary D4 2, 3 0, +1 
    367, 724  
12 (CHD94-138) DHF grade 2 Secondary D2 −2 
    354  
13 (CHD94-095) DHF grade 2 Secondary D2 11 +7 
    196  
14 (CHD94-134) DHF grade 3 Secondary D2 
    372  
15 (KPP94-041) DHF grade 3 Secondary D1 2, 5, 8 −4, −1, +2 
    366  
16 (KPP94-035) DHF grade 3 Secondary D2 +7 
     −  
17 (CHD94-081) DHF grade 3 Secondary D3 −1 
     −  
PatientDiagnosisSerologic ResponseSerotypeAcute/Conv. BleedaStudy DayFever Dayb
1 (CHD94-090) DF Primary D1 4, 11 −1, +6 
    374  
2 (CHD94-067) DF Primary D2 1, 11 −2, +8 
    368  
3 (CHD94-139) DF Secondary D1 2, 3 0, +1 
    354  
4 (KPP94-017) DF Secondary D2 −1 
    366  
5 (CHD94-115) DF Secondary D3 +8 
    725  
6 (CHD94-089) DF Secondary D3 2, 10 −1, +7 
    725  
7 (CHD94-118) DF Secondary D4 2, 3 0, +1 
    367  
8 (KPP94-013) DF Secondary D4 −1 
    364  
9 (CHD94-094) DHF grade 1 Secondary D4 −1 
    336, 725  
10 (CHD94-073) DHF grade 2 Secondary D4 +5 
    368  
11 (CHD94-020) DHF grade 2 Secondary D4 2, 3 0, +1 
    367, 724  
12 (CHD94-138) DHF grade 2 Secondary D2 −2 
    354  
13 (CHD94-095) DHF grade 2 Secondary D2 11 +7 
    196  
14 (CHD94-134) DHF grade 3 Secondary D2 
    372  
15 (KPP94-041) DHF grade 3 Secondary D1 2, 5, 8 −4, −1, +2 
    366  
16 (KPP94-035) DHF grade 3 Secondary D2 +7 
     −  
17 (CHD94-081) DHF grade 3 Secondary D3 −1 
     −  
a

A, acute PBMC samples; C, convalescent samples.

b

Fever day: 0, calendar day when the temperature fell and stayed <38°C.

PBMC from both the acute and convalescent phase of infection (105/well) from each patient were thawed, resuspended in AIM V medium (Life Technologies, Gaithersburg, MD) supplemented with 10% HuAB serum (AIM/10%), and added to a V-bottom 96-well plate in the presence of PHA (1:1000), anti-CD3 (12F6; provided by Johnson Wong, Massachusetts General Hospital, Boston, MA) (0.1 μg/ml), or the indicated concentrations of other Ags. When cytokines were added to the wells, 10 U/ml rIL-2 (Collaborative Biochemical Products, Bedford, MA), 100 U/ml IL-4 (Genzyme, Cambridge, MA), 100 U/ml IL-7 (Genzyme), or 25 ng/ml IL-12 (Genetics Institute, Cambridge, MA) were added to PHA-stimulated or anti-CD3-stimulated cells. A total of 1 × 105 gamma-irradiated (3500 rad) autologous convalescent PBMC or allogeneic PBMC from control donors was added to wells containing PBMC from acute dengue patients, as indicated. The negative controls were cell suspensions in medium alone without any stimulation. Optimal concentrations of Ags to use were determined using control donors. A 1/40 dilution of noninfectious dengue Ags and control Vero cell Ag was used (19). Cells were incubated for 5 to 7 days, as this was shown to be optimal for proliferation using 105 cells/well. The cells were pulsed with [3H]thymidine (on day 4 after the PHA or anti-CD3 stimulation, or on day 6 for dengue Ags and tetanus toxoid) for approximately 18 h before they were harvested and counted in a liquid scintillation counter (1205 Betaplate; Pharmacia, Wallac Oy, Finland).

Cryopreserved PBMC from patients with acute dengue or control healthy donors were thawed. Anti-CD4- and anti-CD8-coated magnetic beads (Dynal, Great Neck, NY) were used to isolate T cells from 2 × 106 PBMC. After the CD4- and CD8-coated beads were adhered to the magnet, the remaining cells were collected and used as a source of non-T cells. The non-T cell population was irradiated (3500 rad). As controls, unfractionated PBMC from both acute dengue patients and control healthy PBMC were stimulated with PHA.

PBMC from four patients with acute dengue infection and control allogeneic PBMC were resuspended at 1 × 106/ml in AIM/10% medium. The transwells (Costar, Cambridge, MA) consist of a lower and upper compartment that are separated by a polycarbonate-treated membrane with pores of 0.4 μm size. A total of 100 μl of acute or control PBMC was added to the upper well of the transwell, and 600 μl of media was added to the lower well with PHA at a final concentration of 1:1000. For coculture experiments, acute PBMC and gamma-irradiated allogeneic PBMC were cultured together in 100 μl in the upper well of the transwell as a positive control. To see whether cell contact was essential to increase proliferation, 100 μl of the acute PBMC was transferred to the upper well and 600 μl of gamma-irradiated, allogeneic PBMC was transferred to the lower well with PHA at 1:1000. The plate was incubated at 37°C. On day 4, 75 μl of the cell suspensions from the upper and lower wells was transferred to a 96-well plate in a final volume of 200 μl, pulsed with 1.25 μCi of [3H]TdR, and harvested approximately 18 h later.

FITC-conjugated mAbs to CD14 and CD19 were purchased from PharMingen (San Diego, CA). The FITC-conjugated CD3, CD4, and CD8 Abs were purchased from Becton Dickinson (Mountain View, CA). The anti-CD28 Abs were purchased from PharMingen and used at a concentration of 5 or 10 μg/ml together with the anti-CD3 Ab 12F6 (0.1 μg/ml) kindly provided by Johnson Wong. FACS analysis was performed on unstimulated PBMC.

We analyzed the proliferative responses of PBMC to mitogens and other Ags from patients with varying grades of severity of dengue illness. PBMC samples obtained from patients at different time points after they were admitted into the study (study day 1 up to study day 11) were tested in this assay (Table I). The responses during acute infection were compared with the proliferation of the same patient’s PBMC obtained 6–24 mo after their acute infection. In all 14 patients, there was a significant decrease in proliferation of acute PBMC in response to stimulation with PHA (Fig. 1). In the four patients tested, there was a decrease in the response to dengue Ag and also to a recall Ag tetanus toxoid in the acute samples of PBMC (Table II). Background cpm of acute PBMC were consistently much lower in all patients compared with their convalescent PBMC, but the stimulation indices (cpm of mitogen- or Ag-stimulated cells ÷ cpm of cells in medium) still indicated a substantial decrease in acute PBMC proliferation compared with convalescent PBMC (Table II and data not shown). The results indicate that in vitro proliferative responses of PBMC to mitogens and specific Ags are suppressed in all grades of acute dengue infection. Samples tested up to 11 days after the patient was admitted into the study showed decreased responses compared with the same individual’s convalescent samples.

FIGURE 1.

PBMC from patients with acute dengue infection do not respond in vitro to mitogen stimulation. A total of 1 × 105 acute and convalescent PBMC from patients was stimulated with a 1/1000 dilution of PHA. Patient numbers are given along the vertical axis with acute sample numbers (A, study day) in parenthesis. All convalescent bleeds were obtained at 1 yr or later after infection, except for number 13, obtained at 6 mo. For patients 9 and 11, the 2-yr bleed was used in this assay as the convalescent sample. Cells were pulsed with [3H]TdR for 18 h and harvested 5 days after incubation at 37°C. The data presented are from nine different experiments performed.

FIGURE 1.

PBMC from patients with acute dengue infection do not respond in vitro to mitogen stimulation. A total of 1 × 105 acute and convalescent PBMC from patients was stimulated with a 1/1000 dilution of PHA. Patient numbers are given along the vertical axis with acute sample numbers (A, study day) in parenthesis. All convalescent bleeds were obtained at 1 yr or later after infection, except for number 13, obtained at 6 mo. For patients 9 and 11, the 2-yr bleed was used in this assay as the convalescent sample. Cells were pulsed with [3H]TdR for 18 h and harvested 5 days after incubation at 37°C. The data presented are from nine different experiments performed.

Close modal
Table II.

PBMC obtained during acute dengue infection do not respond to dengue Ags and recall Ags in [3H]TdR proliferation assaya

Patient No.Study DayDengue AgTetanus ToxoidNo Ag
A1 141 140 128 
 C336 14,166 45,391 387 
11 A3 80 58 49 
 C367 2,939 5,090 227 
14 A4 78 55 58 
 C372 2,094 1,370 169 
15 A5 83 80 75 
 C366 2,344 5,376 856 
Patient No.Study DayDengue AgTetanus ToxoidNo Ag
A1 141 140 128 
 C336 14,166 45,391 387 
11 A3 80 58 49 
 C367 2,939 5,090 227 
14 A4 78 55 58 
 C372 2,094 1,370 169 
15 A5 83 80 75 
 C366 2,344 5,376 856 
a

A total of 1 × 105 PBMC from acute and convalescent phases of infection from the same patient were stimulated with a 1/40 dilution of dengue Ag or a 1/5000 dilution of tetanus toxoid and incubated for 6 days in a 96-well plate at 37°C. Cells were pulsed with [3H]TdR on day 6 for 18 h and harvested. The results presented are from four different experiments performed. Data are mean cpm of two or three replicates.

To characterize the immunologic unresponsiveness of the acute PBMC, we treated the PHA-stimulated cells with 10 U/ml of rIL-2. Inadequate production of IL-2 by T cells is thought to be one of the factors that contribute to the immunosuppression seen during acute measles and CMV infection (5, 9). In eight of nine patients tested, the decreased responses were restored by the addition of exogenous IL-2 (Table III). In one patient (number 12), addition of up to 100 U/ml of IL-2 did not restore proliferation (data not shown). Addition of 1 × 105 gamma-irradiated, autologous convalescent, or allogeneic control PBMC also improved proliferative responses of acute PBMC (Table III). Our data show that the unresponsive acute PBMC can be induced to proliferate by the addition of the cytokine IL-2 and by irradiated, control PBMC. These results, however, do not indicate whether soluble factors released from or cell contact with the irradiated PBMC are essential to restore the proliferation of the acute PBMC.

Table III.

Decreased proliferative responses of acute PBMC are partially restored upon the addition of IL-2, gamma-irradiated autologous or allogeneic PBMCa

Patient No.bPHAPHA + IL-2PHA + Irradiated PBMC
AutologousAllogeneic
2 (A1) 308 62,514 NDc ND 
3 (A3) 899 23,637 ND 23,146 
5 (A9) 4,600 73,073 22,886 ND 
7 (A3) 627 17,593 59,555 ND 
9 (A1) 1,049 26,314 ND ND 
10 (A9) 3,240 71,969 ND ND 
12 (A2) 102 128 ND ND 
13 (A11) 3,917 54,815 130,788 ND 
16 (A9) 1,396 64,821 ND ND 
Patient No.bPHAPHA + IL-2PHA + Irradiated PBMC
AutologousAllogeneic
2 (A1) 308 62,514 NDc ND 
3 (A3) 899 23,637 ND 23,146 
5 (A9) 4,600 73,073 22,886 ND 
7 (A3) 627 17,593 59,555 ND 
9 (A1) 1,049 26,314 ND ND 
10 (A9) 3,240 71,969 ND ND 
12 (A2) 102 128 ND ND 
13 (A11) 3,917 54,815 130,788 ND 
16 (A9) 1,396 64,821 ND ND 
a

A total of 10 U/ml of rIL-2 or 1 × 105 gamma-irradiated autologous convalescent (for patients 5, 7, and 13) or allogeneic healthy PBMC (for patient 3) were added to acute PBMC stimulated with a 1/1000 dilution of PHA and incubated for 5 days. Cells were pulsed overnight on day 4 with [3H]TdR and harvested. The results presented are from eight different experiments performed. Data are mean cpm of two or three replicates.

b

Acute sample numbers are indicated in parenthesis.

c

ND, not done.

To determine whether cell contact with the irradiated PBMC is needed to mediate proliferation, we used a transwell system in which acute cells were separated from allogeneic control PBMC by a polycarbonate membrane. When acute and gamma-irradiated allogeneic cells were incubated together in the upper well, there was a substantial increase in proliferation compared with acute T cells alone stimulated with PHA (Fig. 2). When gamma-irradiated PBMC were separated from the acute cells in the upper well by a polycarbonate membrane, however, proliferation was much lower in all four patients’ PBMC compared with when the cells were incubated together. In patient 6, acute cells proliferated somewhat when they were separated from the gamma-irradiated control cells by the membrane (approximately 30,000 cpm compared with 135,000 cpm), suggesting that both cell-soluble factors and cell contact were important in restoring proliferation. The results, however, suggest that cell contact with gamma-irradiated allogeneic PBMC is predominantly required to restore proliferation of acute cells.

FIGURE 2.

Acute PBMC from patients with dengue require contact with control PBMC to increase proliferative responses. A total of 1 × 105 acute PBMC was added to the upper well of the transwell. A total of 6 × 105 gamma-irradiated allogeneic control PBMC was added in 100 μl to the upper well of the transwell. In the transwell experiment, 1 × 105 acute PBMC were added to the upper well, and 6 × 105 gamma-irradiated allogeneic PBMC were added to the upper or lower well of the transwell, as indicated. cpm of the irradiated allogeneic PBMC incubated with PHA was less than 1148 cpm. Patient numbers are given along the x-axis, and sample numbers of the acute bleeds are given in parenthesis. The results presented are from two different experiments performed.

FIGURE 2.

Acute PBMC from patients with dengue require contact with control PBMC to increase proliferative responses. A total of 1 × 105 acute PBMC was added to the upper well of the transwell. A total of 6 × 105 gamma-irradiated allogeneic control PBMC was added in 100 μl to the upper well of the transwell. In the transwell experiment, 1 × 105 acute PBMC were added to the upper well, and 6 × 105 gamma-irradiated allogeneic PBMC were added to the upper or lower well of the transwell, as indicated. cpm of the irradiated allogeneic PBMC incubated with PHA was less than 1148 cpm. Patient numbers are given along the x-axis, and sample numbers of the acute bleeds are given in parenthesis. The results presented are from two different experiments performed.

Close modal

To further demonstrate that there is a defect in the accessory cells of acute PBMC, both T and non-T cells were isolated from patients with acute dengue and mixed in proliferation assays with T and non-T cells from a control donor. When T cells from a control donor were added to gamma-irradiated non-T cells from the acute PBMC, responses were substantially reduced, indicating that the non-T cells in the acute PBMC sample could not support the proliferation of T cells from a control donor (Table IV). In contrast, when T cells from an acute patient were mixed with non-T cells from a control donor, substantial proliferation was observed. The results indicate that the T cells in the sample of acute PBMC from dengue patients are able to respond when optimal stimuli from the PBMC of a control donor are provided, and indicate that the primary defect in the acute PBMC appears to lie in the APC population.

Table IV.

Non-T cells from acute PBMC of patients with dengue infection cannot support the proliferation of healthy T cellsa

Patient No. (acute samples)
10 (A9)13 (A11)15 (A2)
T (acute PBMC)+ γ non-T (acute PBMC)+ PHA 308 67 199 
T (acute PBMC)+ γ non-T (healthy PBMC)+ PHA 15,302 16,661 12,693 
T (healthy PBMC)+ γ non-T (healthy PBMC)+ PHA 21,671 5,028 7,471 
T (healthy PBMC)+ γ non-T (acute PBMC)+ PHA 1,420 3,534 736 
γ non-T (healthy PBMC)+ PHA 727 339 911 
γ non-T (acute PBMC)+ PHA 70 38 116 
Acute PBMC+ PHA 409 616 99 
Healthy; PBMC+ PHA 45,830 45,830 25,671 
Patient No. (acute samples)
10 (A9)13 (A11)15 (A2)
T (acute PBMC)+ γ non-T (acute PBMC)+ PHA 308 67 199 
T (acute PBMC)+ γ non-T (healthy PBMC)+ PHA 15,302 16,661 12,693 
T (healthy PBMC)+ γ non-T (healthy PBMC)+ PHA 21,671 5,028 7,471 
T (healthy PBMC)+ γ non-T (acute PBMC)+ PHA 1,420 3,534 736 
γ non-T (healthy PBMC)+ PHA 727 339 911 
γ non-T (acute PBMC)+ PHA 70 38 116 
Acute PBMC+ PHA 409 616 99 
Healthy; PBMC+ PHA 45,830 45,830 25,671 
a

T cells were isolated from acute PBMC of patients with dengue infection or healthy control PBMC and mixed with non-T cells from either healthy or acute PBMC. For patient 10, 26,000 T cells and 110,000 non-T cells were added per well; for patient 13, 22,000 T cells and 70,000 non-T cells were added per well; and for patient 15, 12,000 T cells and 33,000 non-T cells were added per well. Cells were incubated at 37°C for 5 days, pulsed, and then harvested. PBMC from patients 10 and 13 were tested in the same experiment, and PBMC from patient 15 were tested in a separate experiment.

To analyze whether costimulatory molecules may play a role in the cell-mediated suppression of acute phase cells, we treated the PBMC of six subjects with anti-CD28 and anti-CD3 Abs. In three patients (numbers 6, 13, and 15), addition of anti-CD28 restored proliferation of acute PBMC to levels comparable with stimulation with anti-CD3 + IL-2 (Fig. 3). The PBMC samples from these patients were obtained at least 8 days after enrollment, at which time the subjects were no longer febrile or viremic (17). PBMC from three other patients (numbers 3, 7, and 17) did not respond to costimulation with either 5 or 10 μg of anti-CD28. The PBMC were obtained from these patients when they had the most severe symptoms (days 2 or 3 after they were enrolled into the study) and were acutely ill in the hospital. Study days 2 or 3 also represent days when the absolute monocyte counts drop to the lowest levels. The results suggest that anti-CD28 Abs can restore proliferation of PBMC samples when the patients are recovering from illness, but have no effect on PBMC obtained from the patients at the peak of their illness.

FIGURE 3.

Anti-CD28 Abs increase proliferation of anti-CD3-stimulated acute PBMC obtained at later time points during acute infection. A total of 1 × 105 acute PBMC was stimulated with 0.1 μg/ml of anti-CD3 Abs, anti-CD3 + anti-CD28 (10 μg/ml), or anti-CD3 + IL-2 (10 U/ml) for 5 days. Cells were pulsed overnight and harvested. Patient numbers are given along the x-axis, and acute sample numbers in parenthesis. The results presented are from four different experiments performed. ∗, Not done.

FIGURE 3.

Anti-CD28 Abs increase proliferation of anti-CD3-stimulated acute PBMC obtained at later time points during acute infection. A total of 1 × 105 acute PBMC was stimulated with 0.1 μg/ml of anti-CD3 Abs, anti-CD3 + anti-CD28 (10 μg/ml), or anti-CD3 + IL-2 (10 U/ml) for 5 days. Cells were pulsed overnight and harvested. Patient numbers are given along the x-axis, and acute sample numbers in parenthesis. The results presented are from four different experiments performed. ∗, Not done.

Close modal

We found a significant decrease in the number and percentage of monocytes in the acute samples of PBMC compared with the convalescent samples (Table V); however, there was no decrease in either the CD4 or CD8 T cells in the acute PBMC. Therefore, a reduction in the number of T cells cannot be the primary reason for inadequate proliferative responses. There were also no differences in the percentage of B cells during acute infection. These results suggest that one of the reasons for the decrease in cell-mediated responses in children with acute dengue infection may be the decreased number of monocytes that would result in fewer total costimulatory ligands such as B7-1 and B7-2 and adhesion molecules available to activate the T cells in the acute samples.

Table V.

Percent of T cells, monocytes, and B cells in acute and convalescent PBMC populationsa

PatientSample No.% T Cells% Monocytes% B Cells
CD4CD8
A8 27 21 28 
 C354 25 12 26 25 
A9 21 20 19 
 C725 15 23 17 
13 A11 ND ND 23 
 C196   13 22 
PatientSample No.% T Cells% Monocytes% B Cells
CD4CD8
A8 27 21 28 
 C354 25 12 26 25 
A9 21 20 19 
 C725 15 23 17 
13 A11 ND ND 23 
 C196   13 22 
a

Frozen PBMC from acute and convalescent samples were thawed from each patient, stained for various markers with FITC-conjugated Abs to CD4, CD8, CD14, and CD19, and analyzed by flow cytometry.

Since receptors for the cytokines IL-2, IL-4, IL-7, and IL-15 are known to share a common γ-chain, we examined whether some of these cytokines would also help overcome the unresponsiveness of the acute phase PBMC. We chose IL-12 as a cytokine that did not utilize the γ-chain as a control. In four of the four patients tested, the acute samples of PBMC responded to IL-2 or IL-7, but not to IL-4 even at a concentration of 500 U/ml (Fig. 4 and data not shown). The results indicate that not all cytokines that share a common γ-chain receptor are able to restore the proliferation of the PBMC obtained during acute infection.

FIGURE 4.

Acute PBMC respond to CD3 + IL-7 stimulation, but not IL-4 or IL-12 stimulation. A total of 1 × 105 cells was stimulated with 0.1 μg/ml of anti CD3 Abs and either 10 U/ml IL-2, 100 U/ml IL-4, 100 U/ml IL-7, or 25 ng/ml IL-12, and incubated for 5 days. Cells were pulsed with [3H]TdR on day 4 overnight and harvested. The results presented are from two different experiments performed. Patient numbers are given along the x-axis, and acute sample numbers in parenthesis.

FIGURE 4.

Acute PBMC respond to CD3 + IL-7 stimulation, but not IL-4 or IL-12 stimulation. A total of 1 × 105 cells was stimulated with 0.1 μg/ml of anti CD3 Abs and either 10 U/ml IL-2, 100 U/ml IL-4, 100 U/ml IL-7, or 25 ng/ml IL-12, and incubated for 5 days. Cells were pulsed with [3H]TdR on day 4 overnight and harvested. The results presented are from two different experiments performed. Patient numbers are given along the x-axis, and acute sample numbers in parenthesis.

Close modal

This study is the first report of impaired cell-mediated responses of the PBMC of patients with acute dengue infection. The results demonstrate decreased in vitro proliferative responses of PBMC to mitogens and to several Ags during acute dengue infection. All of the responses of PBMC from children with acute dengue infection were compared with the responses of PBMC obtained from the same patients 6–24 mo after the infection.

Suppression of in vitro proliferation of acute phase PBMC was observed in subjects with either DHF, the more severe form of dengue illness, or DF, the milder form, in subjects experiencing either primary or secondary dengue infections, and in subjects infected with any of the four serotypes of dengue virus. A variety of mechanisms for virus-induced immunosuppression has been suggested, including abnormalities of T cells upon antigenic challenge in vitro and various defects in the APCs (3, 6, 20, 21, 22). Since the background cpm was lower in acute PBMC in all cases, it could imply that the acute cells cultured in media alone were more susceptible to apoptosis. However, the addition of gamma-irradiated feeders, IL-2, IL-7, or anti-CD28 Abs restored proliferation of the acute T cells, indicating that these cells could be rescued. T lymphocytes from patients with HIV or EBV, and in acute LCMV infection have been shown to undergo apoptosis in vitro upon stimulation (23, 24, 25, 26). In EBV infection, T cell death could be prevented by the addition of IL-2; however, in acute LCMV infection, IL-2 sensitized non-LCMV-specific memory T cells for apoptosis upon subsequent stimulation (26). These studies, however, did not examine whether the accessory cell population contributed to the observed immunosuppression.

To test whether one cell type predominantly accounts for the unresponsiveness of the PBMC, we separated T and non-T cells and performed mixing experiments. The results demonstrate that the dominant abnormality lies in the accessory cells in the acute PBMC, because both acute and control T cells are incapable of responding to PHA in the presence of irradiated acute non-T cells. In contrast, proliferation of the T cells in the acute PBMC increased substantially when irradiated non-T cells from a control donor were present. The defect in the accessory cell population in the acute PBMC is not exclusively an Ag-processing defect because it was also observed with mitogens. The accessory cells in the acute PBMC sample might fail to provide an adequate stimulus or might provide a negative signal to the T cells from samples of acute or control PBMC. Incubation of acute PBMC with autologous convalescent PBMC did not suppress the proliferation of the convalescent PBMC (data not shown), suggesting that the acute phase PBMC do not present a negative signal. Therefore, we believe during acute dengue infection the accessory cells in the PBMC are unable to provide the necessary stimulus to activate the T cells. Accessory cells are necessary to help polyclonal activation of T cells with PHA by cross-linking of the TCR and by providing second signals or soluble factors to induce activation (27). Although we cannot entirely exclude the possibility that a small proportion of the acute T cells is triggered into activation-induced cell death, our results indicate that the primary defect is in the APC population.

Cell contact-dependent and soluble factors released from APCs have been shown to mediate unresponsiveness of T cells. The soluble factors include TNF-dependent release of arachidonic acid and PGE2 by CMV-infected monocytes (22); release of IFN-α from monocytes followed by cell death of the mitogen-stimulated cells (28) in measles and an undescribed cytokine in suppressing Ag-specific proliferation by measles virus (29). Inhibition of proliferation of Ag-specific T cells by human rhinoviruses was shown to be dependent on virion binding to ICAM-1 on monocytes (30). Karp et al. have shown that cross-linking of the measles virus receptor CD46 inhibited monocyte production of IL-12, which is known to be important for the generation of cell-mediated responses (20). All of these studies have carefully analyzed the unresponsiveness of T cells following in vitro infection of either monocytes or PBMC with the respective viruses and then examined the effect of these infected monocytes/PBMC on T cell proliferation. How this relates to the observed suppression seen during or following in vivo infection with any of these viruses is still in question.

Our rationale for using the transwell system was to see whether irradiated autologous or allogeneic PBMC would restore proliferation of the T cells in the acute PBMC by the release of soluble factors. If this was the case, the acute cells should have proliferated when separated by a membrane from the irradiated allogeneic PBMC. Since the patients’ acute cells had significantly lower proliferation when separated by the membrane, these results suggest that the initial triggering of acute PBMC by irradiated control PBMC requires cell-cell contact. It is possible that soluble growth factors are produced by the acute T cells as a result of this initial cell contact-dependent stimulation, which can then restore proliferation. This may explain why cytokines such as IL-2 or IL-7, which are produced downstream of signaling events, increase the proliferation of the acute PBMC. The inability of the PBMC from one patient to respond to even high doses of IL-2 may reflect a more severe immunosuppression, and this patient did exhibit more severe disease manifestations (DHF grade 2). Since we had limited number of PBMC from this patient, it was not possible to further characterize this defect.

The absolute monocyte and absolute neutrophil counts are transiently decreased in patients with dengue illness compared with children with other febrile illnesses (15). The in vitro T cell responses we have observed are significantly depressed for at least 2 wk after the appearance of fever in these patients. Depletion of monocytes from PBMC of control donors decreases the anti-CD3 response, but not the PHA response, whereas depletion of B cells does not affect the proliferation of PBMC (data not shown). This suggests that decreases in the monocyte count in the acute PBMC of the dengue patients do not appear to solely account for the marked in vitro suppression observed.

Plasma levels of IL-10 are increased in patients with DF and DHF (S. Green et al., manuscript submitted). IL-10 is a cytokine with known immunosuppressive properties (31, 32). It down-regulates monocyte production of costimulatory molecules including B7-1 and B7-2, suppresses proliferation, and induces alloantigen-specific unresponsiveness of human CD8+ T cells (33). It is possible that increased levels of IL-10 in dengue patients in vivo alter the expression of costimulatory molecules on monocytes, making them incapable of activating T cells in the presence of mitogens.

Addition of CD28 Abs did not induce T cell proliferation of the acute samples of PBMC obtained on study day 2 or 3, when patients are typically viremic and have their most severe symptoms of disease. When the patients were recovering from their acute illness and the monocyte levels were slowly returning back to normal levels, the CD28 Abs improved proliferation of acute PBMC samples (Fig. 4). It is possible that the addition of costimulatory molecules at the earlier stage of illness cannot trigger sufficient production of IL-2 required for T cell proliferation, and therefore had no effect on the proliferation in the acute PBMC samples. Previous studies of patients with measles and CMV have not examined the effect of anti-CD28 Abs on acute T cell proliferation. It is interesting to speculate in acute dengue infection that decreased B7 molecules preferentially trigger the high affinity receptor CTL activation Ag-4 (instead of the low affinity receptor CD28), which has been shown to provide inhibitory signals and prevent proliferation (34, 35). Other interactions between T cells and APCs such as CD40/CD40 ligand and LFA-3/ICAM-1 may also be important to generate a good immune response.

The receptors for several cytokines, e.g., IL-2, IL-4, IL-7, IL-13, and IL-15, have common motifs and share the γc-chain (36). IL-2, IL-4, IL-7, IL-9, and IL-15 can all act as T cell growth factors, activate the same Jak family tyrosine kinases, but induce different STAT proteins (36). Purified CD4 T cells that had been anergized by ligation of CD4 with HIV gp120 were unable to respond to anti-TCR Abs. Addition of IL-2, IL-4, or IL-7 restored proliferation of these cells, whereas cytokines that bound to receptors without the γc-chain (IL-6 and IL-12) could not (37). Our data indicate that IL-2 or IL-7, but not IL-4, can restore proliferation of PBMC obtained during acute dengue infection. Therefore, although these cytokines share common receptor motifs, there appears to be selectivity in the ability of the acute cells to respond to them.

The suppression of in vitro proliferation seen in measles infection is associated with in vivo immune defects. The tuberculin skin test response is depressed during acute measles from before the appearance of the rash until 7 to 20 days afterward (38). Children with measles are more susceptible to secondary infections, which contribute to nearly one million measles-related deaths worldwide each year (4). There are no published studies on the susceptibility to secondary infections after acute dengue virus infections. Delayed-type hypersensitivity responses have also not been examined in patients with acute dengue. Unlike measles, mucosal surfaces are not involved in dengue infections; however, studies of the in vivo implications of these in vitro observations may be warranted. It would be of interest to perform in vivo testing of delayed-type hypersensitivity of dengue patients to an Ag such as purified protein derivative.

We thank Jurand Janus for the preparation of dengue viral Ags. We thank the nurses and pediatricians at the Queen Sirkit National Institute of Child Health and the Kamphaeng Phet Provincial Hospital, Thailand, for volunteer enrollment and patient management. We thank the research nurses, technicians, technologists, and administrative personnel of the Department of Virology, Armed Forces Research Institute of Medical Sciences (Bangkok, Thailand), for specimen collection, specimen processing, and data management. We also thank the patients and their families for their participation in this study. The contents of this work are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Defense, the Government of the Kingdom of Thailand, or the National Institutes of Health.

1

This work was supported by Grant POI-AI34533 from the National Institutes of Health and by the U.S. Army Medical Research and Materiel Command.

4

Abbreviations used in this paper: s, soluble; DF, dengue fever; DHF, dengue hemorrhagic fever.

1
Carney, W. P., M. S. Hirsch.
1981
. Mechanisms of immunosuppression in cytomegalovirus mononucleosis.
J. Infect. Dis.
144
:
47
2
Hirsch, R. L., D. E. Griffin, R. T. Johnson, S. J. Cooper, I. Lindo De Soriano, S. Rodenbeck, A. Vaisberg.
1984
. Cellular Immune responses during complicated and uncomplicated measles virus infections of man.
Clin. Immunol. Immunopathol.
31
:
1
3
Rouse, B. T., D. W. Horohov.
1986
. Immunosuppression in viral infections.
Rev. Infect. Dis.
8
:
850
4
Borrow, P., M. B. A. Oldstone.
1995
. Measles virus-mononuclear cell interactions.
Curr. Top. Microbiol. Immunol.
191
:
85
5
Griffin, D. E., T. R. Moench, R. T. Johnson, I. Lindo De Soriano, A. Vaisberg.
1986
. Peripheral blood mononuclear cells during natural measles virus infection: cell surface phenotypes and evidence for activation.
Clin. Immunol. Immunopathol.
40
:
305
6
Griffin, D. E., B. J. Ward, L. M. Esolen.
1994
. Pathogenesis of measles virus infection: an hypothesis for altered immune responses.
J. Infect. Dis.
170
: (Suppl. 1):
S24
7
Ward, B. J., R. T. Johnson, A. Vaisberg, E. Jauregui, D. E. Griffin.
1991
. Cytokine production in vitro and the lymphoproliferative defect of natural measles virus infection.
Clin. Immunol. Immunopathol.
61
:
236
8
Arneborn, P., G. Biberfeld.
1983
. T-lymphocyte subpopulations in relation to immunosuppression in measles and varicella.
Infect. Immun.
39
:
29
9
Ward, B. J., D. E. Griffin.
1993
. Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response.
Clin. Immunol. Immunopathol.
67
:
171
10
Lenschow, D. J., T. L. Waulnas, J. A. Bluestone.
1996
. CD28/B7 system of T cell costimulation.
Annu. Rev. Immunol.
14
:
233
11
Yi-qun, Z., K. Lorre, M. De Boer, J. L. Ceuppens.
1997
. B7-blocking agents, alone or in combination with cyclosporin A, induce antigen-specific anergy of human memory T cells.
J. Immunol.
1997
:
4734
12
Sfikakis, P. P., C. S. Via.
1997
. Expression of CD28, CTLA4, CD80 and CD86 molecules in patients with autoimmune rheumatic diseases: implications for immunotherapy.
Clin. Immunol. Immunopathol.
83
:
195
13
Folzenlogen, D., M. F. Hofer, D. Y. M. Leung, J. H. Freed, M. K. Newell.
1997
. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients.
Clin. Immunol. Immunopathol.
83
:
199
14
Kurane, I., B. L. Innis, S. Nimmannitya, A. Nisalak, A. Meager, J. Janus, F. A. Ennis.
1991
. Activation of T lymphocytes in dengue virus infections: high levels of soluble interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-γ in sera of children with dengue.
J. Clin. Invest.
88
:
1473
15
Kalayanarooj, S., D. W. Vaughn, S. Nimmannitya, S. Green, S. Suntayakorn, N. Kunentrasai, W. Viramitrachai, S. Ratanachu-eke, S. Kiatpolpoj, B. L. Innis, A. L. Rothman, A. Nisalak, F. A. Ennis.
1997
. Early clinical and laboratory indicators of acute dengue illness.
J. Infect. Dis.
176
:
313
16
LaRussa, V. F., B. L. Innis.
1995
. Mechanisms of dengue virus-induced bone marrow suppression.
Baillieres Clin. Haematol.
8
:
249
17
Vaughn, D. W., S. Green, S. Kalayanarooj, B. L. Innis, S. Nimmannitya, S. Suntayakorn, A. L. Rothman, F. A. Ennis, A. Nisalak.
1997
. Dengue in the early febrile phase: viremia and antibody responses.
J. Infect. Dis.
176
:
322
18
Anonymous, A..
1997
.
Dengue Hemorrhagic Fever: Diagnosis, Treatment, Prevention and Control
World Health Organization, Geneva.
19
Gagnon, S. J., W. Zeng, I. Kurane, F. A. Ennis.
1996
. Identification of two epitopes on the dengue 4 virus capsid protein recognized by a serotype-specific and a panel of serotype-crossreactive human CD4+ cytotoxic T-lymphocyte clones.
J. Virol.
70
:
141
20
Karp, C. L., M. Wysocka, L. M. Wahl, J. M. Ahearn, P. J. Cuomo, B. Sherry, G. Trinchieri, D. E. Griffin.
1996
. Mechanism of suppression of cell-mediated immunity by measles virus.
Science
273
:
228
21
Fugier-Vivier, I., C. Servet-Delprat, P. Rivailler, M.-C. Rissoan, Y.-J. Liu, C. Rabourdin-Combe.
1997
. Measles virus suppresses cell-mediated immunity by interfering with the survival and functions of dendritic and T cells.
J. Exp. Med.
186
:
813
22
Nokta, A. M., I. M. Hassan, K. Loesch, B. R. Pollard.
1996
. Human cytomegalovirus-induced immunosuppression.
J. Clin. Invest.
97
:
2635
23
Lauener, R. P., S. Huttner, M. Buisson, J. P. Hossle, M. Albisetti, J.-M. Seigneurin, R. A. Seger, D. Nadal.
1995
. T-cell death by apoptosis in vertically human immunodeficiency virus-infected coincides with expansion of CD8+/interleukin-2 receptor/HLA-DR+ T cells: sign of a possible role for herpes viruses as cofactors.
Blood
86
:
1400
24
Uehara, T., T. Miyawaki, K. Ohta, Y. Tamaru, S. Nakamura, N. Taniguchi.
1992
. Apoptotic cell death of primed CD45RO+ T lymphocytes in Epstein-Barr virus-induced infectious mononucleosis.
Blood
80
:
452
25
Tamaru, Y., T. Miyawaki, K. Iwai, T. Tsuji, R. Nibu, A. Yachie, S. Koizumi, N. Taniguchi.
1993
. Absence of bcl-2 expression by activated CD45RO+ T lymphocytes in acute infectious mononucleosis supporting their susceptibility to programmed cell death.
Blood
82
:
521
26
Razvi, E. S., R. M. Welsh.
1993
. Programmed cell death of T lymphocytes during acute viral infection: a mechanism for virus-induced immune deficiency.
J. Virol.
67
:
5754
27
Paul, W. E..
1993
.
Fundamental Immunology
92
Raven Press, New York.
28
Salonen, R., J. Ilonen, A. A. Salmi.
1989
. Measles virus inhibits lymphocyte proliferation in vitro by two different mechanisms.
Clin. Exp. Immunol.
75
:
376
29
Sun, X., J. B. Burns, J. M. Howell, R. S. Fujinami.
1998
. Suppression of antigen-specific T cell proliferation by measles virus infection: role of a soluble factor in suppression.
Virology
246
:
24
30
Gern, J. E., B. Joseph, D. M. Galagan, W. R. Borcherding, E. C. Dick.
1996
. Rhinovirus inhibits antigen-specific T cell proliferation through an intercellular adhesion molecule-1-dependent mechanism.
J. Infect. Dis.
174
:
1143
31
Schols, D., E. De Clercq.
1996
. Human immunodeficiency virus type 1 gp120 induces anergy in human peripheral blood lymphocytes by inducing interleukin-10 production.
J. Virol.
70
:
4935
32
Taga, K., G. Tosato.
1992
. IL-10 inhibits human T cell proliferation and IL-2 production.
J. Immunol.
148
:
1143
33
Groux, H., M. Bigler, J. E. de Vries, M.-G. Roncarolo.
1998
. Inhibitory and stimulatory effects of Il-10 on human CD8+ T cells.
J. Immunol.
160
:
3188
34
Thompson, C. B., J. P. Allison.
1997
. The emerging role of CTLA-4 as an immune attenuator.
Immunity
7
:
445
35
Waulnas, T. A., D. J. Lenschow, C. Y. Bakker, P. S. Linsley, G. J. Freeman, J. M. Green, C. B. Thompson, J. A. Bluestone.
1994
. CTLA-4 can function as a negative regulator of T cell activation.
Immunity
1
:
405
36
Lin, J.-X., T.-S. Migone, M. Tsang, M. Friedmann, J. A. Weatherbee, L. Zhou, A. Yamauchi, E. T. Bloom, J. Mietz, S. John, J. W. Leonard.
1995
. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13 and IL-15.
Immunity
2
:
331
37
Selliah, N., T. H. Finkel.
1998
. JAK3 activation and rescue of T cells from HIV gp120-induced unresponsiveness.
J. Immunol.
160
:
5697
38
Tamashiro, V. G., H. H. Perez, D. E. Griffin.
1987
. Prospective study of the magnitude and duration of changes in tuberculin reactivity during complicated and uncomplicated measles.
Pediatr. Infect. Dis. J.
6
:
451